2025-07-23 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data, formatted as requested:

## Johnson & Johnson (JNJ) Stock Analysis

Johnson & Johnson is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer health products.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 23.71%
*   **VOO Cumulative Return:** 97.07%
*   **Absolute Divergence:** -76.0 (JNJ underperformed VOO by 76 percentage points)
*   **Relative Divergence:** 6.8 (JNJ's relative divergence compared to VOO is 6.8 on scale of 0~100)

**Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) over the analyzed period. The absolute divergence of -76 indicates a substantial difference in cumulative returns. The relative divergence of 6.8 suggests that JNJ's performance is near the bottom of its historical range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | 28.0% | 56.1% | -1.0%   | -0.0  | 336.2  |
| 2016-2018  | 8.0%  | 56.6% | -10.0%  | 0.0   | 310.5  |
| 2017-2019  | 18.0% | 56.6% | -12.0%  | 0.7   | 351.0  |
| 2018-2020  | 12.0% | 59.2% | -8.0%   | 0.3   | 378.7  |
| 2019-2021  | 32.0% | 59.6% | -16.0%  | 0.2   | 411.6  |
| 2020-2022  | 7.0%  | 61.4% | 5.0%    | 0.2   | 425.0  |
| 2021-2023  | -15.0% | 61.4% | -33.0%  | 0.4   | 377.1  |
| 2022-2024  | -35.0% | 61.4% | -61.0%  | 0.3   | 348.0  |
| 2023-2025  | -4.0%  | 70.1% | -52.0%  | 0.2   | 404.1  |

**Analysis:** The table shows varying performance across different periods. Noticeable trends include:

*   **Declining Alpha:** The Alpha figures are generally negative, indicating underperformance compared to the benchmark, especially in recent years.
*   **Relatively Low Beta:** Beta values are consistently low (close to 0), suggesting that JNJ's price movements are not strongly correlated with the overall market.
*   **Increasing MDD:** The Maximum Drawdown (MDD) has generally been increasing, indicating greater potential losses from peak to trough.
*   **Capitalization:** Market Cap has flactuated.

### 2. Recent Price Action

*   **Current Price:** 167.93
*   **Previous Close:** 164.36
*   **Change:** 2.17
*   **5-day Moving Average:** 164.75
*   **20-day Moving Average:** 157.3255
*   **60-day Moving Average:** 154.9498

**Analysis:** The price shows a recent positive movement (change of 2.17). The fact that the current price is above all three moving averages (5, 20, and 60-day) suggests a short-term upward trend.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3359 (Low Risk)
*   **RSI:** 76.28 (Overbought)
*   **PPO:** 0.7537
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34) (Cash Ratio: 0% on 2025-07-08)
*   **Delta_Previous_Relative_Divergence (20-day):** 4.2 (+) (Short-term Increase)
*   **Expected Return:** -413.2%

**Analysis:**

*   **MRI:** The low MRI suggests relatively low market risk associated with JNJ.
*   **RSI:** The RSI value is in overbought territory, potentially indicating a possible pullback in the near future.
*   **PPO:** The Positive indicator shows the long term average price is above the short term.
*   **Delta_Previous_Relative_Divergence:** The positive change in relative divergence suggests a recent improvement in JNJ's performance relative to the S&P 500, although it is from a low base.
*   **Expected Return:** The very negative expected return (-413.2%) is a major red flag, suggesting that, based on the model, long-term investment in JNJ, relative to the S&P 500, is projected to underperform significantly. The recent price change (2.17) confirms some short-term positive momentum.

### 4. Recent News & Significant Events

*   **2025-07-21:** Major business developments, regulatory changes, or market events.
*   **2025-07-22:** Analysts are discussing Johnson & Johnson's performance and outlook.
*   **2025-07-19:** Stock volatility due to recent news, earnings reports, or executive actions.
*   **2025-07-20:** Market experts highlight risks and opportunities.

**Analysis:** Recent news suggests the stock is experiencing volatility and is subject to significant market and industry scrutiny. Investors should monitor these developments closely.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출      |
|--------------|------|-----------|
| 2025-04-23   | 4.57 | 21.89 B$  |
| 2024-10-23   | 1.12 | 22.47 B$  |
| 2024-07-25   | 1.95 | 22.45 B$  |
| 2024-05-01   | 1.35 | 21.38 B$  |
| 2025-04-23   | 1.35 | 21.38 B$  |

**Analysis:** The earnings data is mixed. The most recent EPS is significantly higher than previous quarters. Revenue has fluctuated but remains relatively stable. The duplicate entry for 2025-04-23 with different EPS values needs clarification, as it may be an error.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-03-31   | $21.89B   | 66.40%        |
| 2024-12-31   | $22.52B   | 68.35%        |
| 2024-09-30   | $22.47B   | 69.01%        |
| 2024-06-30   | $22.45B   | 69.40%        |
| 2024-03-31   | $21.38B   | 69.55%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-03-31   | $78.11B   | 14.08%  |
| 2024-12-31   | $71.49B   | 4.80%   |
| 2024-09-30   | $70.16B   | 3.84%   |
| 2024-06-30   | $71.54B   | 6.55%   |
| 2024-03-31   | $70.02B   | 4.65%   |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable over the past year, with a slight increase followed by a recent decrease.
*   **Profit Margin:** Profit margins are generally high, indicating strong profitability, but have decreased slightly in the most recent quarter.
*   **Equity:** Equity has increased significantly, likely due to retained earnings and/or stock issuance.
*   **ROE:** Return on Equity (ROE) has fluctuated but shows a significant spike in the most recent quarter, likely driven by the increase in EPS.

### 7. 종합적인 분석

**Overall Assessment:**

Johnson & Johnson (JNJ) is a stable, large-cap company, but the data paints a mixed picture:

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 over the analyzed period and is expected to continue to do so, according to the negative "Expected Return."
*   **Recent Positive Momentum:** There's evidence of recent positive price movement and improved short-term relative performance.
*   **High Profitability:** Profit margins and ROE are generally strong, but there have been declines in profit margin and increase in ROE.
*   **Mixed Technical Signals:** The RSI suggests the stock may be overbought. The MRI indicates low market risk.
*   **Uncertainty:** Recent news and earnings volatility suggest caution.

**Conclusion:**

While JNJ appears to be financially sound, its underperformance compared to the S&P 500 and the negative long-term expected return are concerning. Recent positive price action and news events warrant close monitoring. Investors should carefully consider their risk tolerance and investment goals before making any decisions regarding JNJ. The conflicting signals from technical indicators and the negative expected return suggest a cautious approach is warranted. Further investigation into the reasons behind the underperformance and the recent spike in EPS and Equity is recommended.
